Notice
This is not the latest version of this item. The latest version can be found at:https://dspace.mit.edu/handle/1721.1/138388.2
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
| dc.contributor.author | Wang, D | |
| dc.contributor.author | Zhang, F | |
| dc.contributor.author | Gao, G | |
| dc.date.accessioned | 2021-12-08T18:08:11Z | |
| dc.date.available | 2021-12-08T18:08:11Z | |
| dc.date.issued | 2020-04-02 | |
| dc.identifier.uri | https://hdl.handle.net/1721.1/138388 | |
| dc.description.abstract | © 2020 Elsevier Inc. Wang, Zhang, and Gao discuss the progress, concerns, and challenges currently facing CRISPR-based therapeutics, a field that has inspired renewed but cautious interest in human genome editing. | en_US |
| dc.language.iso | en | |
| dc.publisher | Elsevier BV | en_US |
| dc.relation.isversionof | 10.1016/j.cell.2020.03.023 | en_US |
| dc.rights | Creative Commons Attribution-NonCommercial-NoDerivs License | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
| dc.source | PMC | en_US |
| dc.title | CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Wang, D, Zhang, F and Gao, G. 2020. "CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors." Cell, 181 (1). | |
| dc.relation.journal | Cell | en_US |
| dc.eprint.version | Author's final manuscript | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dc.date.updated | 2021-12-08T18:05:55Z | |
| dspace.orderedauthors | Wang, D; Zhang, F; Gao, G | en_US |
| dspace.date.submission | 2021-12-08T18:05:56Z | |
| mit.journal.volume | 181 | en_US |
| mit.journal.issue | 1 | en_US |
| mit.license | PUBLISHER_CC | |
| mit.metadata.status | Authority Work and Publication Information Needed | en_US |
